26 terminated. 26 Phase 2, 4 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 26 | Terminated 26 |
| Phase 1 | 4 | Terminated 4 |
| Phase 3 | 3 | Terminated 3 |
Follow Scleroderma, Systemic: new trials by email Literature Review of Scleroderma, Systemic trials Research Report on Scleroderma, Systemic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis KYV-101, Standard lymphodepletion regimen - Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous | Phase 1 / Phase 2 | Terminated | Kyverna Therapeutics | 3 | 2024-08-06 | 2026-08-31 |
| An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc) HZN-825 - Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic | Phase 2 | Terminated | Amgen | 174 | 2022-11-04 | 2026-01-05 |
| Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH Riociguat Oral Tablet, Placebo - Pulmonary Vascular Disorder, Primary Pulmonary Hypertension | Phase 2 | Terminated | Heidelberg University | 35 | 2022-10-24 | 2026-01-21 |
| A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis HZN-825 BID, Placebo, HZN-825 QD - Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic | Phase 2 | Terminated | Amgen | 301 | 2021-11-05 | 2026-03-20 |
| A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis Temanogrel, Placebo - Raynaud's Phenomenon Secondary to Systemic Sclerosis | Phase 2 | Terminated | Pfizer | 13 | 2021-11-03 | 2023-12-22 |
| COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders Moderna mRNA-1273, BNT162b2, Ad26.COV2.S - Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE) | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 258 | 2021-08-13 | 2026-06-10 |
| A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients Ixazomib - Systemic Sclerosis, Scleroderma | Phase 2 | Terminated | Michael M. Pham | 4 | 2021-04-28 | 2025-04-06 |
| Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis Belumosudil - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Terminated | Kadmon, a Sanofi Company | 10 | 2021-03-03 | 2023-06-05 |
| A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea) FCX-013, veledimex - Morphea, Scleroderma, Localized | Phase 1 / Phase 2 | Terminated | Castle Creek Biosciences, LLC. | 1 | 2019-12-18 | 2024-01-23 |
| A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis GLPG1690 - Systemic Sclerosis | Phase 2 | Terminated | Lakefront Biotherapeutics NV | 31 | 2019-07-18 | 2022-03-29 |
| KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis Belumosudil (KD025), Placebo - System; Sclerosis, Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Terminated | Kadmon, a Sanofi Company | 36 | 2019-06-26 | 2023-08-30 |
| Cardiac Safe Transplants for Systemic Sclerosis Rituximab, Fludarabine, Cyclophosphamide - Systemic Sclerosis, Scleroderma | Phase 2 / Phase 3 | Terminated | Northwestern University | 9 | 2018-05-17 | 2020-08-12 |
| Abituzumab in SSc-ILD Abituzumab 1500 mg, Abituzumab 500 mg, Placebo - Systemic Sclerosis-associated Interstitial Lung Disease | Phase 2 | Terminated | EMD Serono Research & Development Institute, Inc. | 24 | 2016-05-31 | 2019-06-18 |
| Subcutaneous Injection of Autologous Adipose Tissue-derived Stromal Vascular Fraction Into the Fingers of Patients With Systemic Sclerosis Stromal Vascular fraction, Ringer lactate - Scleroderma, Systemic | Phase 2 | Terminated | Assistance Publique Hopitaux De Marseille | 40 | 2015-09-01 | 2019-03-05 |
| Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis JBT-101, Placebo, Part B Open-Label Extension - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Terminated | Corbus Pharmaceuticals Inc. | 42 | 2015-08-01 | 2021-04-21 |
| Exparel as a Nerve Block for Severe Hand Pain liposomal bupivacaine - CREST Syndrome, Peripheral Vascular Disease | Phase 2 / Phase 3 | Terminated | Jose Soberon, MD | 13 | 2014-11-01 | 2024-05-21 |
| Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease Pomalidomide (CC-4047), Placebo - Scleroderma, Systemic, Sclerosis, Systemic | Phase 2 | Terminated | Celgene | 23 | 2012-08-09 | 2023-12-01 |
| A Clinical Trial for CTD-ILD Treatment N-Acetylcysteine - Interstitial Lung Disease, Connective Tissue Disease | Phase 2 / Phase 3 | Terminated | University of Michigan | 5 | 2011-12-01 | 2017-04-06 |
| Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon ORM-12471 30mg, ORM-12471, placebo - Raynaud's Phenomenon | Phase 2 | Terminated | Orion Corporation, Orion Pharma | 15 | 2011-03-01 | 2014-06-27 |
| Open-Label Study of Oral Treprostinil in Digital Ulcers treprostinil diethanolamine - Systemic Sclerosis | Phase 2 | Terminated | United Therapeutics | 115 | 2009-09-01 | 2024-06-18 |
Showing 20 of 26. Sign in to see all of them.
Scleroderma, Diffuse (15) · Lung Diseases, Interstitial (4) · Raynaud Disease (3) · Arthritis, Rheumatoid (2) · Autoimmune Diseases (2) · Dermatomyositis (2) · Hypertension, Pulmonary (2) · Pulmonary Fibrosis (2) · digital ulcers (2) · Arthritis, Juvenile (1) · COVID-19 (1) · CREST Syndrome (1) · Connective Tissue Diseases (1) · Familial Primary Pulmonary Hypertension (1)
Skin and Connective Tissue Diseases (26) · Connective Tissue Diseases (25) · Skin Diseases (25) · Lung Diseases (8) · Respiratory Tract Diseases (8) · Cardiovascular Diseases (6) · Vascular Diseases (5) · Embolism and Thrombosis (3) · Immune System Diseases (3) · Livedoid Vasculopathy (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Skin Diseases, Vascular (3) · Thrombosis (3)
Bosentan (2) · Cyclophosphamide (2) · KD025 (2) · belumosudil (2) · fludarabine (2) · 2019-nCoV Vaccine mRNA-1273 (1) · APD791 (1) · Abituzumab (1) · Acetylcysteine (1) · Ad26COVS1 (1) · Antilymphocyte Serum (1) · BNT162 Vaccine (1) · BNT162b5 (1) · COVID-19 Vaccines (1) · Drug Delivery Systems (1)
Amgen (2) · Kadmon, a Sanofi Company (2) · Assistance Publique Hopitaux De Marseille (1) · Castle Creek Biosciences, LLC. (1) · Celgene (1) · Charite University, Berlin, Germany (1) · Corbus Pharmaceuticals Inc. (1) · EMD Serono Research & Development Institute, Inc. (1) · Georgetown University (1) · Heidelberg University (1) · Jose Soberon, MD (1) · Kyverna Therapeutics (1) · Lakefront Biotherapeutics NV (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Michael M. Pham (1)
United States (17) · United Kingdom (8) · Italy (5) · Spain (5) · Germany (4) · Canada (3) · France (3) · Poland (3) · Argentina (2) · Australia (2) · Israel (2) · Serbia (2) · Switzerland (2) · Austria (1) · Belgium (1)
Amit Bar-Or, MD, FRCP (1) · Ariane L Herrick, MB,ChB, MD (1) · Dinesh Khanna, MBBS, MSc (1) · Gabriela Riemekasten, MD (1) · James Seibold, MD (1) · Jan T Gran, Professor (1) · Janet E Pope, MD MPH FRCPC (1) · Jose Soberon, MD (1) · Judith A. James, MD, PhD (1)
PMID 18634152, PMID 24489014, PMID 24850877, PMID 32612255, PMID 33004536, PMID 34297066, PMID 40088930, PMID 41289027, PMID 42457022
2014 (1), 2015 (1), 2019 (1), 2023 (1)